Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,054 matching trials from the live ClinicalTrials.gov search.
Conditions
Melanoma
Interventions
Fianlimab, Cemiplimab, Pembrolizumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
Conditions
Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions
Infliximab + Prednisone, Methylprednisolone + Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Conditions
Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, ipilimumab
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
16 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Dysplastic Nevus, Health Status Unknown, Melanoma, No Evidence of Disease
Interventions
Best Practice, mySmartCheck, Survey Administration
Other · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
Interventions
Acasunlimab, Pembrolizumab
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Melanoma
Interventions
Skin Self Examination Information and ABCDE Rule
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Maywood, Illinois • Lebanon, New Hampshire
Conditions
Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions
Itraconazole, Rifampin, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Interventions
TRX518
Biological
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Uveal Melanoma
Interventions
RP2, Ipilimumab, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Conditions
Melanoma (Skin)
Interventions
filgrastim, therapeutic autologous dendritic cells
Biological
Lead sponsor
Baylor Health Care System
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Melanoma
Interventions
relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Anchorage, Alaska • Phoenix, Arizona • San Francisco, California + 6 more
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer
Interventions
AMG 228
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
La Jolla, California • New Haven, Connecticut • New York, New York
Conditions
Melanoma (Skin)
Interventions
hu14.18-IL2 fusion protein
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma, Spinal Cord Compression
Interventions
Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide, biopsy, immunohistochemistry staining method, flow cytometry, polymerase chain reaction
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Melanoma
Interventions
Interferon alpha
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Conditions
Non-melanoma Skin Cancer
Interventions
Solaraze and Vaniqa
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama
Conditions
Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Conditions
Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Interventions
Video Education, Genetic Counseling
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Melanoma (Skin)
Interventions
Detox-B adjuvant, verteporfin
Biological · Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
6
States / cities
Denver, Colorado • Aventura, Florida • Miami Beach, Florida + 3 more
Conditions
Melanoma
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Louisville, Kentucky • Pittsburgh, Pennsylvania • Houston, Texas
Conditions
Melanoma
Interventions
APX005M, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas